Neurol. praxi. 2016;17(1):63-66 | DOI: 10.36290/neu.2016.013
Teriflunomide in treating relapsing-remitting multiple sclerosis - immunomodulatory mechanisms
- Ústav klinické imunologie a alergologie Lékařské fakulty Masarykovy univerzity a FN u sv. Anny,
- Centrum pro výzkum toxických látek v prostředí (RECETOX) Přírodovědecké fakulty Masarykovy univerzity v Brně
Multiple sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system through demyelination and neurodegeneration. Autoreactive lymphocytes penetrate the blood-brain barrier to attack the nervous system. Teriflunomide has recently been approved as a treatment of relapsing forms of MS. The main therapeutic effect is considered to be mediated via the inhibition of the de novo synthesis of pyrimidine leading to a reduction in proliferation of activated T and B cells without causing cell death. Vaccination with inactivated vaccines is possible during treatment with teriflunomide and leads to sufficient immune response.
Keywords: multiple sclerosis, teriflunomide, immunomodulation, autoimmunity, PML, vaccination
Published: February 1, 2016 Show citation
References
- Bar-Or A. Teriflunomide (Aubagio(R)) for the treatment of multiple sclerosis. Exp Neurol. 2014; 262: 57-65.
Go to original source... 
Go to PubMed... - Bar-Or A, Freedman MS, Kremenchutzky M, Menguy-Vacheron F, Bauer D, Jodl S, Truffinet P, Benamor M, Chambers S, O'Connor PW. Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis. Neurology. 2013; 81(6): 552-558. Go to original source... Go to PubMed...
- Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014; 74(6): 659-674. Go to original source... Go to PubMed...
- Bar-Or A, Wiendl H, Miller B, Benamor M, Truffinet P, Church M, Menguy-Vacheron F. Randomized study of teriflunomide effects on immune responses to neoantigen and recall antigens. Neurol Neuroimmunol Neuroinflamm. 2015; 2(2): e70. doi: 10.1212/NXI.0000000000000070. Go to original source... Go to PubMed...
- Bayas A, Mäurer M. Teriflunomide for the treatment of relapsing-remitting multiple sclerosis: patient preference and adherence. Patient Prefer Adherence. 2015; 9: 265-274. Go to original source... Go to PubMed...
- Brent RL. Teratogen update: reproductive risks of leflunomide (Arava); a pyrimidine synthesis inhibitor: counseling women taking leflunomide before or during pregnancy and men taking leflunomide who are contemplating fathering a child. Teratology. 2001; 63(2): 106-112. Go to original source... Go to PubMed...
- Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(3): 247-256. Go to original source... Go to PubMed...
- Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand. 2011 Aug; 124(2): 75-84. Go to original source... Go to PubMed...
- Kieseier BC, Benamor M. Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis. Neurol Ther. 2014; 3(2): 133-138. Go to original source... Go to PubMed...
- Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, Bauer D, Benamor M, Truffinet P, O'Connor PW; TOPIC Study Group. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014; 13(10): 977-986. Go to original source... Go to PubMed...
- Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343(13): 938-52. Go to original source... Go to PubMed...
- O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, Benzerdjeb H, Truffinet P, Wang L, Miller A, Freedman MS; TEMSO Trial Group. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011; 365(14): 1293-1303. Go to original source... Go to PubMed...
- Oh J, O'Connor PW. Established disease-modifying treatments in relapsing-remitting multiplesclerosis. Curr Opin Neurol. 2015; 28(3): 220-209. Go to original source... Go to PubMed...
- Paul F, Ruprecht K. Aktuelle Immuntherapie der Multiplen Sklerose. Nervenarzt. 2015; 86(8): 1031-1042. Go to original source... Go to PubMed...
- Selmi C, Mix E, Zettl UK. A clear look at the neuroimmunology of multiple sclerosis and beyond. Autoimmun Rev. 2012; 11(3): 159-162. Go to original source... Go to PubMed...
- Tallantyre E, Evangelou N, Constantinescu CS. Spotlight on teriflunomide. Int MS J. 2008; 15(2): 62-68. Go to PubMed...
- Thon V. Imunologické aspekty moderní léčby roztroušené sklerózy. Klinická imunológia a alergológia. 2015; in press.
- Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler. 2014; 20(6): 705-716. Go to original source... Go to PubMed...
- Warnke C, Stüve O, Kieseier BC Teriflunomide for the treatment of multiple sclerosis. Clin Neurol Neurosurg. 2013; 115(Suppl 1): S90-94. Go to original source... Go to PubMed...